CA2864746A1 - Methods, compounds and compositions for treatment of influenza and parainfluenza patients - Google Patents

Methods, compounds and compositions for treatment of influenza and parainfluenza patients Download PDF

Info

Publication number
CA2864746A1
CA2864746A1 CA2864746A CA2864746A CA2864746A1 CA 2864746 A1 CA2864746 A1 CA 2864746A1 CA 2864746 A CA2864746 A CA 2864746A CA 2864746 A CA2864746 A CA 2864746A CA 2864746 A1 CA2864746 A1 CA 2864746A1
Authority
CA
Canada
Prior art keywords
patient
das181
viral
sialidase
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2864746A
Other languages
English (en)
French (fr)
Inventor
Ron Moss
Tiejun Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ansun Biopharma Inc
Original Assignee
Ansun Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc filed Critical Ansun Biopharma Inc
Publication of CA2864746A1 publication Critical patent/CA2864746A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2864746A 2012-02-17 2013-02-19 Methods, compounds and compositions for treatment of influenza and parainfluenza patients Abandoned CA2864746A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261600545P 2012-02-17 2012-02-17
US61/600,545 2012-02-17
US201261727627P 2012-11-16 2012-11-16
US61/727,627 2012-11-16
PCT/US2013/026754 WO2013123521A1 (en) 2012-02-17 2013-02-19 Methods, Compounds and Compositions for Treatment of Parainfluenza Virus in Immunocompromised Patients

Publications (1)

Publication Number Publication Date
CA2864746A1 true CA2864746A1 (en) 2013-08-22

Family

ID=48984833

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2864746A Abandoned CA2864746A1 (en) 2012-02-17 2013-02-19 Methods, compounds and compositions for treatment of influenza and parainfluenza patients

Country Status (9)

Country Link
US (5) US20130280332A1 (enExample)
EP (1) EP2841092B1 (enExample)
JP (1) JP2015508780A (enExample)
CN (2) CN109529026A (enExample)
AU (3) AU2013221230A1 (enExample)
CA (1) CA2864746A1 (enExample)
ES (1) ES2970401T3 (enExample)
IL (2) IL234116B (enExample)
WO (1) WO2013123521A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
ES2606958T3 (es) 2010-05-14 2017-03-28 Dana-Farber Cancer Institute, Inc. Compuestos de tienotriazolodiazepina para tratar una neoplasia
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
MX2016009974A (es) 2014-01-31 2016-10-31 Dana Farber Cancer Inst Inc Derivados de diaminopirimidina bencensulfona y sus usos.
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
WO2015131113A1 (en) 2014-02-28 2015-09-03 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
RU2017104897A (ru) 2014-08-08 2018-09-10 Дана-Фарбер Кэнсер Инститьют, Инк. Производные диазепана и их применения
WO2016022970A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
UA122130C2 (uk) 2014-10-27 2020-09-25 Тенша Терапеутікс, Інк. Інгібітори бромодомену
CA2964629A1 (en) 2014-11-06 2016-05-12 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
BR112017009440A2 (pt) * 2014-11-06 2017-12-19 Dana Farber Cancer Inst Inc uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd)
WO2016200916A1 (en) * 2015-06-08 2016-12-15 Ansun Biopharma, Inc. Treatment of human metapneumovirus
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
US11306105B2 (en) 2015-09-11 2022-04-19 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
CR20180336A (es) 2015-11-25 2018-08-06 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos
WO2017184999A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
AU2020391178A1 (en) * 2019-11-25 2022-06-09 Ansun Biopharma, Inc. Immune cell delivery of sialidase to cancer cells, immune cells and the tumor microenvironment
JP2024540218A (ja) 2021-11-02 2024-10-31 アンサン バイオファーマ， インコーポレイテッド Ｄａｓ１８１バリアント組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7334580B2 (en) * 2002-05-07 2008-02-26 Smaldone Gerald C Methods, devices and formulations for targeted endobronchial therapy
EP1539284B1 (en) * 2002-09-06 2020-01-29 Philip Morris Products S.a.s. Aerosol generating device and method for generating aerosols
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
AU2003294401C1 (en) 2002-11-22 2008-09-18 Ansun Biopharma, Inc. Broad spectrum anti-viral therapeutics and prophylaxis
WO2007114881A1 (en) * 2006-01-24 2007-10-11 Nexbio, Inc. Technology for preparation of macromolecular microspheres
AU2010315024B2 (en) * 2009-11-06 2015-02-12 Nexbio, Inc. Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract

Also Published As

Publication number Publication date
AU2019226190B2 (en) 2021-10-07
CN109529026A (zh) 2019-03-29
IL273194B2 (en) 2023-02-01
US20130280332A1 (en) 2013-10-24
AU2019226190A1 (en) 2019-09-26
AU2013221230A1 (en) 2014-10-02
EP2841092A4 (en) 2015-09-16
AU2017258955A1 (en) 2017-12-14
US20210046165A1 (en) 2021-02-18
EP2841092C0 (en) 2023-12-06
JP2015508780A (ja) 2015-03-23
HK1207975A1 (en) 2016-02-19
EP2841092A1 (en) 2015-03-04
ES2970401T3 (es) 2024-05-28
US20250387457A1 (en) 2025-12-25
US20170151315A1 (en) 2017-06-01
CN104203267A (zh) 2014-12-10
IL273194B (en) 2022-10-01
WO2013123521A1 (en) 2013-08-22
IL234116B (en) 2020-03-31
US20150132274A1 (en) 2015-05-14
IL273194A (en) 2020-04-30
EP2841092B1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
US20250387457A1 (en) Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients
EP4232073B1 (en) New dosage regimen for inhaled vasoactive intestinal polypeptide
EP2496251A1 (en) Methods, compounds and compositions for treatment and prophylaxis in the respiratory tract
US20120231088A1 (en) Use of Deuterium Oxide for the Treatment of Virus-Based Diseases of the Respiratory Tract
CN115427576B (zh) 包括透明质酸和蛋白聚糖连接蛋白1的用于预防或治疗肺部疾病的组合物
US20080260863A1 (en) Compositions for mucociliary clearance and methods for administering same
KR102750010B1 (ko) 호흡기 바이러스 감염의 치료 또는 예방을 위한 수퍼옥시드 디스무타아제 활성을 갖는 폴리펩티드 및 세포외 소포체의 용도
EP2544705B1 (en) Interferon beta for use in the treatment of lower respiratory tract illness caused by influenza
AU2019389806B2 (en) Methods and compositions for preventing or treating acute exacerbations with polyclonal immunoglobulin
WO2005120556A1 (fr) Medicament a base de lysozyme humain, son procede de preparation et ses applications
HK1207975B (en) Compounds and compositions for use in a method of treatment of parainfluenza virus
US12083135B2 (en) Use of a nitrogen-containing bisphosphonate in combination with a glucocorticoid in preventing or treating viral pneumonia
CN108926707B (zh) Pf4的抗rsv应用
HK40004532A (en) Methods, compounds and compositions for treating influenza and parainfluenza patients
Arruda et al. Update on therapy of influenza and rhinovirus infections
WO2021228875A1 (en) Treatment of respiratory viral infections
KR20230013133A (ko) 폴리뉴클레오타이드를 포함하는 약물조성물 및 그 covid-19 예방 또는 치료에 사용되는 용도
US20250186474A1 (en) Pharmaceutical solution composition and oral mist inhaler comprising the same
WO2024096742A1 (en) SARS-CoV-2 BINDING POLYPEPTIDE
WO2023198757A1 (en) Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
WO2024096743A1 (en) Sars-cov-2 binding antibody
EA048350B1 (ru) Применение даларгина для профилактики орви и предотвращения развития осложнений при заболеваниях орви

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180116

FZDE Discontinued

Effective date: 20220704